Clinical Trial Update: Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial comparing ruxolitinib to prednisone as first-line systemic therapy for chronic graft-versus-host disease (cGVHD) is currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• PREDNISONE (Prednisone)
• Ruxolitinib (Jakafi) (ruxolitinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Chronic Graft-versus-host Disease (cGVHD) | Phase 2 | Status: RECRUITING